Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer - PubMed
3 hours ago
- #gastric cancer
- #antibody-drug conjugate
- #clinical trial
- Telisotuzumab adizutecan (ABBV-400) is a c-Met-targeting antibody-drug conjugate evaluated in a phase 1 trial for advanced gastric/gastroesophageal junction adenocarcinoma.
- The study included 42 patients with advanced disease who had received 1-2 prior therapies, treated with 3.0 mg/kg every 3 weeks.
- Efficacy results showed an objective response rate of 29%, clinical benefit rate of 71%, median progression-free survival of 4.0 months, and median overall survival of 5.8 months.
- Safety profile was manageable, with all patients experiencing treatment-emergent adverse events, including 88% grade ≥3 events, most commonly anemia (67%) and nausea (52%).
- Biomarker analysis indicated better response in patients with higher c-Met expression and MET focal amplification, supporting further development, including combination therapies.